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BACKGROUND: Cardiac arrhythmias are remarkably common and routinely go undiagnosed because they
are often transient and asymptomatic. Effective diagnosis and treatment can substantially reduce the
morbidity and mortality associated with cardiac arrhythmias. The Zio Patch (iRhythm Technologies, Inc,
San Francisco, Calif) is a novel, single-lead electrocardiographic (ECG), lightweight, Food and Drug
Administrationecleared, continuously recording ambulatory adhesive patch monitor suitable for detecting
cardiac arrhythmias in patients referred for ambulatory ECG monitoring.
METHODS: A total of 146 patients referred for evaluation of cardiac arrhythmia underwent simultaneous
ambulatory ECG recording with a conventional 24-hour Holter monitor and a 14-day adhesive patch
monitor. The primary outcome of the study was to compare the detection arrhythmia events over total wear
time for both devices. Arrhythmia events were deﬁned as detection of any 1 of 6 arrhythmias, including
supraventricular tachycardia, atrial ﬁbrillation/ﬂutter, pause greater than 3 seconds, atrioventricular block,
ventricular tachycardia, or polymorphic ventricular tachycardia/ventricular ﬁbrillation. McNemar’s tests
were used to compare the matched pairs of data from the Holter and the adhesive patch monitor.
RESULTS: Over the total wear time of both devices, the adhesive patch monitor detected 96 arrhythmia
events compared with 61 arrhythmia events by the Holter monitor (P < .001).
CONCLUSIONS: Over the total wear time of both devices, the adhesive patch monitor detected more events
than the Holter monitor. Prolonged duration monitoring for detection of arrhythmia events using single-
lead, less-obtrusive, adhesive-patch monitoring platforms could replace conventional Holter monitoring
in patients referred for ambulatory ECG monitoring.
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95.e12 The American Journal of Medicine, Vol 127, No 1, January 2014of symptomatic arrhythmia events, there is a growing body
of evidence related to the morbidity and mortality associated
with subclinical arrhythmias often missed by conventional
24-hour monitoring.6
The Holter monitor, ﬁrst introduced in the late 1940s,
remains the most commonly used method for investigatingCLINICAL SIGNIFICANCE
 Extended iRhythm Zio patch monitoring
detected more arrhythmia events than
24-hour Holter monitoring in those
referred for ambulatory electrocardio-
graphic monitoring.
 Extending arrhythmia monitoring
periods results in a greater number of
arrhythmia events to be detected.
 Detection of more arrhythmia events
should result in the prompt recognition
and treatment of clinically signiﬁcant
arrhythmias.
 The iRhythm Zio patch was tolerated
better by patients than the Holter
monitor.patients in the ambulatory setting
with suspected arrhythmias.7 For
the investigation of patients with
palpitations, 24-hour Holter mon-
itoring is reported to have a diag-
nostic yield of 15% to 39%.8-10
Although extended event recorder
monitoring can increase this yield,
their cumbersome form factor
often limits patient activities. Their
utility is further eroded by the fact
that approximately 1 in 4 patients
are unable to activate their event
recorder during a symptomatic
period.8,11 Because many clini-
cally signiﬁcant arrhythmias are
often asymptomatic, their appro-
priate identiﬁcation and treatment
are critical to reducing mortality
and morbidity.
The Zio Patch (iRhythm Tech-
nologies, Inc, San Francisco, Calif)
is a Food and Drug Administration
(FDA)ecleared, single-lead, lightweight, 14-day ambula-
tory ECG adhesive patch monitor (Figure 1). The device
does not have external leads or wires. Unlike the Holter
monitor, its low-proﬁle design and water-resistant proper-
ties allow patients to participate in almost all activities of
daily living with minimal disruption. It can be mailed
directly to the patient and self-applied. Once monitoring is
completed, the patch is mailed to a facility that analyzes the
recorded data, and a report is made available to the ordering
physician.
The Comparison of 24 Hour Holter Monitoring Versus
14 Day Novel Adhesive Patch Electrocardiographic Moni-
toring study is a prospective analysis of patients referred forFigure 1 The Zio Patch (iRhythm Technologies, Inc, San
Francisco, Calif) is an FDA-cleared, single-use, noninvasive,
water-resistant, 14-day, ambulatory ECG monitoring adhesive
patch.evaluation of cardiac arrhythmias by ambulatory ECG
monitoring. We aimed to evaluate the diagnostic utility of a
novel adhesive patch monitor for up to 14 days compared
with standard 24-hour Holter monitoring.MATERIALS AND METHODS
Patient Selection and Data
Collection
The Scripps Institutional Review
Board approved the protocol, and
all patients enrolled gave informed
consent to participate. Between
April 2012 and July 2012, patients
referred to the cardiac investiga-
tions laboratory at Scripps Green
Hospital (La Jolla, Calif) for am-
bulatory ECG monitoring were
ﬁtted with an adhesive patch
monitor and a 24-hour Holter
monitor. Both devices were acti-
vated simultaneously. Patients were
enrolled prospectively in a con-
secutive fashion on the basis of
appropriate eligibility criteria. In-
clusion criteria included an age of
18 years or older and being under
evaluation for cardiac arrhythmia,capable of providing informed consent, and able to
comply with continuous ECG monitoring for up to 14
days. Exclusion criteria were any known skin allergies,
conditions, or sensitivities to any of the components of
the adhesive patch monitor, receiving or anticipated to
receive pacing or external direct current cardioversion
during the monitoring period, or the anticipation of be-
ing exposed to high-frequency surgical equipment during
the monitoring period.
Devices and Study Protocols
The Zio Patch is an FDA-cleared, single-use, noninvasive,
water-resistant, 14-day, ambulatory ECG monitoring adhe-
sive patch. A study coordinator applied the device over the
left pectoral region of the patient’s chest (Figure 1). A
trigger button, integrated into the monitor’s design, can be
activated to create a digital time stamp on the continuously
recorded data stream to synchronize the recorded ECG
rhythm with symptoms. Patients were instructed to activate
the trigger should they experience any suspected symptom
of arrhythmia. Patients also were instructed to wear the
adhesive patch monitor for as long as possible, with the
goal of obtaining up to 14 days of ECG data recording.
On day 14 or at any time point prior, the patient removed
and returned the adhesive patch monitor by means of a
prepaid mail package to iRhythm Technologies, Inc. ECG
data were collected and interrogation was performed using
the manufacturer’s FDA-cleared, proprietary algorithm.
Figure 2 iRhythm Technologies Inc, sample Zio Patch report format.
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ation and quality assurance (Figure 2). This report was
then uploaded to a secure website for independent review
by physician investigators at the Scripps Translational
Science Institute.
Per standard institutional practice, the Holter monitor
was ﬁtted by a cardiac technician and returned at 24 hours
to the cardiac investigation laboratory for interrogation.
Holter monitor data were independently analyzed by
physician investigators at the Scripps Translational Science
Institute. Reports from both the adhesive patch monitor and
the Holter monitor were made available to the referring
physician. Any ECG data that were thought to be of urgent
clinical concern from the Holter monitor or adhesive patch
monitor, as determined by the physician investigators, were
relayed to the referring physician within 24 to 48 hours.
Arrhythmia events were deﬁned as detection of any 1
of 6 arrhythmias, including supraventricular tachycardia
(>4 beats, not including atrial ﬁbrillation or ﬂutter), atrial
ﬁbrillation/ﬂutter (>4 beats), pause >3 seconds, atrioven-
tricular block (Mobitz type II or third-degree atrioven-
tricular block), ventricular tachycardia (>4 beats), or
polymorphic ventricular tachycardia/ventricular ﬁbrillation.
Arrhythmias were categorized into 2 groups. The ﬁrst
consisted of all 6 arrhythmias. The second consisted of the
5 most clinically signiﬁcant arrhythmias, which excluded
supraventricular tachycardia.Table 1 Total Wear Time for Both Devices (Holter 24 Hours, Zio
Patch [iRhythm Technologies, Inc, San Francisco, Calif] Up to
14 Days)
Holter Any 6 (24 h)
No At least 1
Patch any 6 (total wear time) No 49 1
Yes 36 60
Any arrhythmias (of the 6 types atrioventricular block, pause,
polymorphic ventricular tachycardia, supraventricular tachycardia, ven-
tricular tachycardia, or atrial ﬁbrillation) (McNemar’s P < .001).Sample Size Calculations and Statistics
The primary aim of the study was to compare the detection
of arrhythmia events between the adhesive patch monitor
and the Holter monitor over the total wear time of both
devices. Secondary end points included comparison of
detection of arrhythmia events over a simultaneous initial
24-hour period and survey data examining patient prefer-
ence to both devices. Arrhythmia events were analyzed
for 2 arrhythmia groupings including all 6 arrhythmias and
the 5 more clinically signiﬁcant arrhythmias as previously
described. McNemar’s test was used to compare if any 1 of
the 6 arrhythmias or any 1 of 5 more clinically signiﬁcant
arrhythmias were detected by the adhesive patch monitor
versus the Holter monitor for (1a) 24 hours for the Holter
monitor and up to 14 days for adhesive patch monitor
and then for (1b) the ﬁrst 24 hours of observation for both
devices. Descriptive statistics were provided for age, total
wear time, and survey results.
A sample size of at least 120 after attrition achieves
80% power for a 2-tailed McNemar’s test. Because a
planned interim analysis was performed for (1a) when
50% of patients were enrolled, the alpha for the interim
analysis was 0.005 and an alpha of 0.048 was used for the
ﬁnal analysis. The interim analysis requirement was met
(P < .001), and the study was completed.
The study was designed and data were collected by the
Scripps Translational Science Institute. Fought Statistical
Consulting (Chicago, Ill) independently analyzed the data.SAS 9.3 (SAS Institute Inc, Cary, NC) was used to perform
the statistical analyses.
RESULTS
Of the 238 patients screened, 88 declined enrollment. A total
of 150 patients were enrolled, and 4 were lost to follow-up,
3 in the adhesive monitoring patch group and 1 in the Holter
monitoring group. A total of 146 patients with data on both
the 24-hour Holter monitor and the adhesive patch monitor
were included in the ﬁnal analysis. The median age for
patients enrolled was 64 years (range, 22-94 years), and
41.8% of patients were male. The median wear time in days
for the Holter monitor and adhesive patch monitor was 1.0
(range, 0.9-1.0) and 11.1 (range, 0.9-14.0), respectively.
Of the patients with complete survey data, 93.7% (134/
143) found the adhesive monitoring patch comfortable to
wear as opposed to 51.7% (74/143) for the Holter monitor.
The adhesive patch monitor affected 10.5% (15/143) of
patients’ activities of daily living as opposed to 76.2% (109/
143) of patients in the Holter group. When asked whether
they would prefer to wear the adhesive patch monitor or the
Holter monitor, 81% (111/137) chose the adhesive patch
monitor. Of the 102 physicians surveyed, 90% (92/102)
thought a deﬁnitive diagnosis was achieved using data from
the adhesive patch monitor, as opposed to 64% (65/102)
using data from the Holter monitor.
Device Performance Over Total Wear Time
When device data were compared over the total wear time,
the adhesive patch monitor detected signiﬁcantly more
events than the Holter monitor. For all 6 arrhythmias, the
Holter monitor detected 61 arrhythmia events compared
with 96 arrhythmia events by the adhesive patch monitor
(P < .001) (Table 1). Of these events, 60 were detected
by both the Holter monitor and the adhesive patch
monitor. The adhesive patch monitor detected 36 events
that went undetected by the Holter monitor primarily as a
function of prolonged monitoring (Table 1). There was
only 1 instance when the Holter monitor detected at least
1 event and the adhesive patch monitor did not.
Because the substantially increased performance of the
adhesive patch monitor may be a function of detecting less
clinically meaningful supraventricular tachycardias over
an extended monitoring period, supraventricular tachycardia
Table 2 Total Wear Time for Both Devices
Holter Any 5 (24 h)
No At least 1
Patch any 5 (total wear time) No 105 0
Yes 14 27
Any of the 5 clinically relevant arrhythmias (atrioventricular block,
pause, polymorphic ventricular tachycardia, supraventricular tachycardia,
ventricular tachycardia, or atrial ﬁbrillation) (McNemar’s P < .001).
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total number of arrhythmia events detected diminished
for both devices, but the adhesive patch monitor still detected
signiﬁcantly more arrhythmia events than the Holter
monitor, 41 and 27, respectively (P < .001). Of these events,
27 were detected by both the Holter monitor and the adhe-
sive patch monitor. Of note, 14 clinically signiﬁcant arrhy-
thmia events were detected by the adhesive patch monitor
but went undetected by the Holter monitor (Table 2). Over
the total wear time of both devices, the adhesive patch
monitor detected signiﬁcantly more arrhythmia events
when both arrhythmia groups were assessed.
Device Performance Over Simultaneous Initial
24-hour Monitoring Period
As a secondary outcome measure, the adhesive patch
monitor was compared with the Holter monitor for detection
of arrhythmia events over a simultaneous 24-hour period.
In this period, the Holter monitor detected signiﬁcantly
more of the 6 types of arrhythmia events than the adhesive
patch monitor. The Holter monitor detected 61 arrhythmia
events compared with 52 arrhythmia events by the adhesive
patch monitor (P ¼ .013) (Table 3). Of these events, 50
were detected by both the Holter monitor and the adhesive
patch monitor. Of the arrhythmia events detected by 1
device but not the other, the Holter monitor detected 11
arrhythmia events that were undetected by the adhesive
patch monitor in the simultaneous 24-hour period and the
adhesive patch monitor detected 2 arrhythmia events that
were undetected by the Holter monitor. Of the 11 events
undetected by the adhesive patch monitor in the ﬁrst
24 hours, 10 arrhythmia events were subsequently detected
by the adhesive patch monitor beyond 24 hours. Of these
11 events, 8 were the same arrhythmia type as initially
detected by the Holter monitor, with 7 being supraventric-
ular tachycardias and 1 being short runs of ventricularTable 3 Twenty-fourehour Wear Time for Both Devices
Holter Any 6 (24 h)
No At least 1
Patch any 6 (24 h) No 83 11
Yes 2 50
Any arrhythmias (of the 6 types atrioventricular block, pause,
polymorphic ventricular tachycardia, supraventricular tachycardia, ven-
tricular tachycardia, or atrial ﬁbrillation) (McNemar’s P ¼ .013).tachycardia. Of the 3 arrhythmia events that were different,
2 were episodes of supraventricular tachycardia initially
detected by the Holter monitor, but the adhesive monitoring
patch detected paroxysmal atrial ﬁbrillation at greater than
24 hours. The other was a single episode of supraventricular
tachycardia detected by the Holter monitor and with no
arrhythmia events detected by the adhesive patch monitor
beyond 24 hours.
Because supraventricular tachycardia is often of lesser
clinical consequence, the analysis was repeated over the
same initial 24-hour period excluding supraventricular
tachycardias and including only the more clinically signiﬁ-
cant arrhythmias of atrial ﬁbrillation/ﬂutter (>4 beats),
pause >3 seconds, atrioventricular block (Mobitz type II
or third-degree atrioventricular block), ventricular tachy-
cardia (>4 beats), and polymorphic ventricular tachycardia/
ventricular ﬁbrillation. Again, the Holter monitor detected
more events than the adhesive patch monitor, 27 and 24,
respectively, but this did not reach statistical signiﬁcance
(P ¼ .083). Of these events, 24 were detected by both the
Holter monitor and the adhesive patch monitor (Table 4).
Three clinically more signiﬁcant arrhythmia events were
detected by the Holter monitor and not by the adhesive patch
monitor, whereas the adhesive patch monitor did not detect
any events that also were not detected by the Holter monitor.
The beneﬁt of prolonged monitoring is demonstrated by
the fact that of the 3 clinically signiﬁcant arrhythmia events
initially undetected by the adhesive patch monitor in the ﬁrst
day of monitoring, all 3 were subsequently detected with
extended monitoring beyond 24 hours, 2 of which were
short runs of atrial ﬁbrillation and the other a single short
run of ventricular tachycardia. Although the Holter monitor
detected signiﬁcantly more events than the adhesive patch
monitor over the initial 24-hour monitoring period, when
limited to more clinically signiﬁcant events, 3 events went
undetected but were subsequently detected with monitoring
beyond 24 hours.DISCUSSION
The Zio Patch is an FDA-cleared, noninvasive continuous
ambulatory ECG adhesive monitoring patch that is less
cumbersome to wear than a conventional 24-hour Holter
monitor. With 93.7% of patients ﬁnding the adhesive
patch monitor comfortable to wear and 81% indicating they
would prefer it over the Holter monitor, it is clearly a less-
obtrusive and more patient-friendly monitoring platform.Table 4 Twenty-fourehour Wear Time for Both Devices
Holter Any 5 (24 h)
No At least 1
Patch any 5 (24 h) No 119 3
Yes 0 24
Any of the 5 clinically relevant arrhythmias (atrioventricular block,
pause, polymorphic ventricular tachycardia, supraventricular tachycardia,
ventricular tachycardia, or atrial ﬁbrillation) (McNemar’s P ¼ .083).
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achieved more often using the adhesive patch monitor as
opposed to the Holter monitor. The convenience of sending
and returning the adhesive patch by mail and the durable
capture of ECG rhythm data over the substantially longer
monitoring period of up to 14 days offer some distinct
theoretic advantages. However, the reference standard is the
3-lead, 24-hour Holter monitor, and the value of a single-
lead, 14-day adhesive patch monitor needs to be assessed
in comparison with this standard. Our study demonstrated
increased arrhythmia diagnostic yield using the prolonged
adhesive patch monitor compared with conventional
24-hour Holter monitoring.
Although short of the approved 14-day wear time, the
median adhesive patch monitor wear time of 11.1 days in
this study is likely a sufﬁcient diagnostic window to capture
arrhythmia events, because the highest diagnostic yield
for arrhythmia detection is usually the ﬁrst 7 days of
ambulatory ECG monitoring.12 Ambulatory ECG moni-
toring beyond 7 days often provides only an additional
3.9% of patients with a diagnosis.12 Furthermore, the cost
of extended monitoring periods beyond 2 weeks using older
technologic platforms can range up to $5832 per new
diagnosis with a disappointing 0.01 diagnosis per patient
per week after 2 weeks. This compares with a per patient
diagnosis cost of $98 over an initial 7 days and $576 over a
14-day period, again based on older, often more expensive
platforms.12 An average wear time of 11.1 days is then
likely to achieve a reasonable balance of adequate diag-
nostic yield at a reasonable cost per new diagnosis using
newer, potentially cheaper technology. Furthermore, the
adhesive patch monitor can achieve monitoring periods
equal to older event recorder platforms but using less
cumbersome technology.
Consistent with our ﬁndings, there is substantial evidence
to suggest that extending the ECG monitoring period
beyond 24 hours increases the diagnostic yield of arrhy-
thmia diagnosis. To date, however, this could only be ach-
ieved using bulky, activity-limiting technology requiring
multiple chest leads.13 Although previous studies have
demonstrated the incremental diagnostic yield of prolong-
ing the monitoring period, in this study the extended
monitoring was achieved with a more lightweight, unob-
trusive, adhesive, patch device.14-16 Primarily as a func-
tion of extended monitoring, the adhesive patch monitor
detected 36 events that went undetected by the Holter
monitor. Using the incremental diagnostic yield of an
extended monitoring period as opposed to relying on data
acquisition during brief, often asymptomatic periods is
critical, because even prolonged pauses of up to 9.7 seconds
can be asymptomatic.17
Over a simultaneous 24-hour monitoring period, the
Holter monitor detected more arrhythmia events than the
adhesive patch monitor for both groups of arrhythmias used
in this study. The Holter monitor’s performance advantage
in this timeframe, with detection of 11 arrhythmia events not
detected by the adhesive patch monitor, was unexpected andwarranted explanation. A root cause analysis was performed
to determine the reason for these discrepancies, and each of
these cases was then run for a second time through the
iRhythm Technologies algorithm and Quality Assurance
Tool and reviewed in the page view format, which allowed
full visual review of the continuously running ECG data.
Of the 11 discrepant arrhythmia events, 2 can be explained
by an algorithm misclassiﬁcation and 7 by a processing error
by the initial iRhythm Technologies Inc, physician reviewer.
With respect to the algorithm misclassiﬁcations, in one
instance the algorithm did not detect the arrhythmia event
possibly because of transiently reduced signal quality and in
the other instance classiﬁed a brief run of supraventricular
tachycardia as a sinus tachycardia, because it fell into a rate
range just outside of the set supraventricular tachycardia
zone. In light of this, the adhesive patch monitor supra-
ventricular tachycardia zones have been adjusted. As part of
the report generation, an iRhythm physician performs an
initial overview of all detected potential arrhythmia events
and classiﬁes them accordingly. In 7 of the discrepant
arrhythmia event cases, short runs of mostly supraventric-
ular tachycardia were not classiﬁed as such and therefore
were never surfaced to the report viewed by the ordering
physicians or investigators. In-house iRhythm staff training
has been implemented to correct this issue.
In general, the information provided by the Holter
monitors additional 2 ECG leads are an obvious advantage
for both automatic algorithm analysis and physician inter-
pretation. Speciﬁcally, 3-lead recordings allow for the
detection of arrhythmia events characterized by a shift in
electrical axis that can be missed by single-lead recordings.
Multi-lead recordings also allow for improved detection
of aberrant/broader QRS complexes where a single-lead
recording may not detect the altered QRS complex width
because the leading edge or trailing edge of the QRS
complex may be relatively isoelectric to the single-lead
recording vector.
These differences may then apply more so to broad
complex tachycardia arrhythmia detection rather than nar-
row complex arrhythmia detection. Evidence from our study
supports this, with no episode of atrial ﬁbrillation/ﬂutter
detected by the Holter monitor going undetected by the
adhesive.
Of the more clinically meaningful arrhythmia events
initially undetected by the adhesive patch monitor, in the
simultaneous 24-hour monitoring period, all subsequently
had a clinically meaningful arrhythmia event detected
with prolonged monitoring by the adhesive patch monitor.
These arrhythmia events were the same in all 3 cases, with 2
episodes of paroxysmal atrial ﬁbrillation and 1 episode of a
brief run of ventricular tachycardia being detected with
extended monitoring by the adhesive patch monitor.Study Limitations
The patients enrolled included all those referred for ambu-
latory ECG monitoring rather than for determination of a
Barrett et al Comparison of ECG Monitoring Devices 95.e17previously undocumented arrhythmia. Although the major-
ity had no previously documented arrhythmia, several had
preexisting arrhythmias and were referred for reasons other
than symptomatic arrhythmia. In practice, the adhesive
patch monitor is mailed to and self-applied by the patient,
whereas in this study it was applied by a study research
coordinator.CONCLUSIONS
Over the total wear time of both devices, the adhesive
monitoring patch detects signiﬁcantly more arrhythmia
events than the Holter monitor. On the basis of these ﬁnd-
ings, novel, single-lead, prolonged-duration, low-proﬁle
devices may soon replace conventional Holter monitoring
platforms for the detection of arrhythmia events in patients
referred for ambulatory ECG monitoring.
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